Weight Management
Evidence-based approaches to sustainable weight loss
Medical Disclaimer
The compounds with the strongest clinical evidence for weight management, including GLP-1 receptor agonists and metabolic support agents. Educational summary of published trial data.
Protocol Map
Compounds organized by evidence tier. Foundation compounds have the strongest clinical support. Emerging compounds show promise but lack robust human data.
Foundation
GLP-1 receptor agonist for weight management
FDA-approved for chronic weight management. The STEP clinical trial program demonstrated average weight loss of 15-17% of body weight over 68 weeks in non-diabetic adults. The most extensively studied GLP-1 RA for obesity.
Literature dosing: 0.25-2.4 mg weekly SC -- STEP trial titration schedule
Dual GIP/GLP-1 receptor agonist
FDA-approved dual incretin agonist. The SURMOUNT-1 trial showed up to 22.5% body weight reduction at the highest dose. Acts on both GIP and GLP-1 receptors for enhanced metabolic effect.
Literature dosing: 2.5-15 mg weekly SC -- SURMOUNT trial titration schedule
Commonly Added
Insulin sensitization and metabolic support
A biguanide with decades of safety data. Often used alongside GLP-1 RAs for additive insulin sensitization. May also offer modest independent weight benefit via AMPK activation.
Nutritional support during GLP-1 therapy
B12 deficiency is commonly observed during both metformin use and rapid weight loss. Monitoring and supplementation help prevent neurological symptoms and fatigue.
Emerging
GH-mediated body composition improvement
A GHRH analog that stimulates endogenous GH release. Some clinical data suggest favorable shifts in body composition (reduced fat mass, preserved lean mass), though evidence is less robust than for GLP-1 RAs.
GI support during GLP-1 therapy
Some practitioners report using BPC-157 to support GI tolerance during GLP-1 RA titration, based on its gastric origin and preclinical gut-healing data. Human evidence for this specific application is limited.
Recommended Monitoring
Lab work and clinical assessments commonly recommended when pursuing this goal. Your provider will determine the appropriate testing schedule for your situation.
| Test | Frequency | Purpose |
|---|---|---|
| Comprehensive Metabolic Panel | Baseline, 3 months, then every 6 months | Monitor liver function, kidney function, and electrolytes |
| HbA1c | Baseline, 3 months, then every 6 months | Track glycemic control and insulin resistance improvement |
| Fasting Insulin | Baseline, then every 6 months | Assess insulin resistance independently of glucose |
| Thyroid Panel (TSH, Free T4) | Baseline, then annually | GLP-1 RAs carry a precautionary thyroid warning; monitor for changes |
| Lipid Panel | Baseline, then every 6 months | Track cardiovascular risk factor improvement with weight loss |
| CBC | Baseline, then every 6 months | General health screening, monitor for nutritional deficiencies |
| Vitamin B12 | Baseline, then every 6 months if on metformin | Screen for depletion common with metformin and caloric restriction |
Lifestyle Foundations
Caloric deficit through whole-food nutrition is the foundation of any weight management approach. GLP-1 RAs reduce appetite but do not replace the need for dietary quality. Protein intake of at least 0.7 g per pound of body weight helps preserve lean mass during weight loss. Resistance training 2-4 times per week counteracts the muscle loss that accompanies rapid fat loss. Adequate hydration (at minimum 64 oz daily) supports the GI tolerability of GLP-1 therapy.
Related Goals
Find a Provider
The compounds on this page require medical supervision and prescriptions. A qualified provider can evaluate whether these approaches are appropriate for you.
Explore Practical Guides →Important Disclaimer
The information provided on this page is for educational and informational purposes only. It is not intended as, and should not be construed as, medical advice, diagnosis, or treatment. The compounds, dosages, and protocols discussed are summaries of published research and do not constitute prescriptions or treatment plans. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment protocol. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Stay evidence-informed
Get research updates on compounds related to this goal, delivered to your inbox.
By subscribing, you consent to receive email newsletters from Truth In Peptides. You can unsubscribe at any time using the link in any email. We never sell or share your email address. See our Privacy Policy.